Квир-лингвистика: нужна ли она отечественной лингвистической гендерологии?

Статья посвящена квир-лингвистике как новому магистральному направлению развития современной парадигмы гендерных исследований. Подробно разбирается концептуальный аппарат этого направления. Описывается попытка изучения фрагментов языкового сознания носителей русского языка с учетом квир-фактора.Стаття присвячена квір-лінгвістиці як новому магістральному напрямку в розвитку сучасної парадигми гендерних досліджень. Докладно розбирається концептуальний апарат цього напрямку. Описується спроба вивчення фрагментів мовної свідомості носіїв російської мови з урахуванням квір-фактору.The article is targeted at a new discipline in the area of gender and language research – queer linguistics. The conceptual linguistic apparatus and terminology are discussed. The study of verbal responses obtained from Russian –speaking informants (gays and lesbians) as a linguistic construal of their world is analyzed

Refactoring GrPPI:Generic Refactoring for Generic Parallelism in C++

Funding: EU Horizon 2020 project, TeamPlay (https://www.teamplay-xh2020.eu), Grant Number 779882, UK EPSRC Discovery, grant number EP/P020631/1, and Madrid Regional Government, CABAHLA-CM (ConvergenciA Big dAta-Hpc: de Los sensores a las Aplicaciones) Grant Number S2018/TCS-4423.The Generic Reusable Parallel Pattern Interface (GrPPI) is a very useful abstraction over different parallel pattern libraries, allowing the programmer to write generic patterned parallel code that can easily be compiled to different backends such as FastFlow, OpenMP, Intel TBB and C++ threads. However, rewriting legacy code to use GrPPI still involves code transformations that can be highly non-trivial, especially for programmers who are not experts in parallelism. This paper describes software refactorings to semi-automatically introduce instances of GrPPI patterns into sequential C++ code, as well as safety checking static analysis mechanisms which verify that introducing patterns into the code does not introduce concurrency-related bugs such as race conditions. We demonstrate the refactorings and safety-checking mechanisms on four simple benchmark applications, showing that we are able to obtain, with little effort, GrPPI-based parallel versions that accomplish good speedups (comparable to those of manually-produced parallel versions) using different pattern backends.Publisher PDFPeer reviewe

Pregnancy-related pelvic girdle pain: an update

A large number of scientists from a wide range of medical and surgical disciplines have reported on the existence and characteristics of the clinical syndrome of pelvic girdle pain during or after pregnancy. This syndrome refers to a musculoskeletal type of persistent pain localised at the anterior and/or posterior aspect of the pelvic ring. The pain may radiate across the hip joint and the thigh bones. The symptoms may begin either during the first trimester of pregnancy, at labour or even during the postpartum period. The physiological processes characterising this clinical entity remain obscure. In this review, the definition and epidemiology, as well as a proposed diagnostic algorithm and treatment options, are presented. Ongoing research is desirable to establish clear management strategies that are based on the pathophysiologic mechanisms responsible for the escalation of the syndrome's symptoms to a fraction of the population of pregnant women

Predicting new venture survival and growth: does the fog lift?

This paper investigates whether new venture performance becomes easier to predict as the venture ages: does the fog lift? To address this question we primarily draw upon a theoretical framework, initially formulated in a managerial context by Levinthal (Adm Sci Q 36(3):397–420, 1991) that sees new venture sales as a random walk but survival being determined by the stock of available resources (proxied by size). We derive theoretical predictions that are tested with a 10-year cohort of 6579 UK new ventures in the UK. We observe that our ability to predict firm growth deteriorates in the years after entry—in terms of the selection environment, the ‘fog’ seems to thicken. However, our survival predictions improve with time—implying that the ‘fog’ does lift

Unraveling the structure of Mn-promoted Co/TiO2 fischer-tropsch catalysts by in situ x-ray absorption spectroscopy

Combination of in situ X-ray absorption spectroscopy (XAFS) at the Co and Mn K-edges with electron microscopy (STEM-EELS) has allowed to unravel the complex structure of a series of unpromoted and Mn promoted TiO2-supported cobalt Fischer-Tropsch catalysts prepared by homogeneous deposition precipitation (HDP), both in their calcined and reduced states. After calcination the catalysts are generally composed of large Co3O4 aggregates (13-20 nm) and a MnO2-type phase that is either dispersed on the TiO2 surface or, for the major part, covering the Co3O4 particles. Additionally Mn is also forming a spinel-type Co3-xMnxO4 solid solution at the surface of the Co3O4 Particles. In pure Co or when small amount of this spinel-type phase are formed during calcination, reduction in H-2 at 350 degrees C produces Co-0 particles of variable sizes (3.5-15 nm) otherwise Co reduction is limited to the Co2+ state. Manganese that exists entirely in a Mn2+ state in the reduced catalysts is forming (1) a highly dispersed Ti2MnO4-type phase at the TiO2 surface, (2) a less dispersed MnO phase close to the cobalt particles that coexists with (3) a rock salt-type Mn1-x.CoxO solid solution. Similarly, large amount of spinet solid solution in the calcined state favors the formation of Mn1-xCoxO-type solid solution during reduction showing that one of the main roles of the Mn promoter is to limit Co reducibility

Unraveling the Structure of Mn-promoted Co/TiO2 Fischer-Tropsch Catalysts by In Situ X-ray Absorption Spectroscopy

Combination of in situ X-ray absorption spectroscopy (XAFS) at the Co and Mn K-edges with electron microscopy (STEM-EELS) has allowed to unravel the complex structure of a series of unpromoted and Mn promoted TiO2-supported cobalt Fischer-Tropsch catalysts prepared by homogeneous deposition precipitation (HDP), both in their calcined and reduced states. After calcination the catalysts are generally composed of large Co3O4 aggregates (13-20 nm) and a MnO2-type phase that is either dispersed on the TiO2 surface or, for the major part, covering the Co3O4 particles. Additionally Mn is also forming a spinel-type Co3-xMnxO4 solid solution at the surface of the Co3O4 Particles. In pure Co or when small amount of this spinel-type phase are formed during calcination, reduction in H-2 at 350 degrees C produces Co-0 particles of variable sizes (3.5-15 nm) otherwise Co reduction is limited to the Co2+ state. Manganese that exists entirely in a Mn2+ state in the reduced catalysts is forming (1) a highly dispersed Ti2MnO4-type phase at the TiO2 surface, (2) a less dispersed MnO phase close to the cobalt particles that coexists with (3) a rock salt-type Mn1-x.CoxO solid solution. Similarly, large amount of spinet solid solution in the calcined state favors the formation of Mn1-xCoxO-type solid solution during reduction showing that one of the main roles of the Mn promoter is to limit Co reducibility

Fosfomycin Vs Ciprofloxacin as Oral Step-Down Treatment for Escherichia coli Febrile Urinary Tract Infections in Women:A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial

BACKGROUND: We aimed to determine the noninferiority of fosfomycin compared to ciprofloxacin as an oral step-down treatment for Escherichia coli febrile urinary tract infections (fUTIs) in women. METHODS: This was a double-blind, randomized, controlled trial in 15 Dutch hospitals. Adult women who were receiving 2–5 days of empirical intravenous antimicrobials for E. coli fUTI were assigned to step-down treatment with once-daily 3g fosfomycin or twice-daily 0.5g ciprofloxacin for 10 days of total antibiotic treatment. For the primary end point, clinical cure at days 6–10 post-end of treatment (PET), a noninferiority margin of 10% was chosen. The trial was registered on Trialregister.nl (NTR6449). RESULTS: After enrollment of 97 patients between 2017 and 2020, the trial ended prematurely because of the coronavirus disease 2019 pandemic. The primary end point was met in 36 of 48 patients (75.0%) assigned to fosfomycin and 30 of 46 patients (65.2%) assigned to ciprofloxacin (risk difference [RD], 9.6%; 95% confidence interval [CI]: –8.8% to 28.0%). In patients assigned to fosfomycin and ciprofloxacin, microbiological cure at days 6–10 PET occurred in 29 of 37 (78.4%) and 33 of 35 (94.3%; RD, –16.2%; 95% CI: –32.7 to –0.0%). Any gastrointestinal adverse event was reported in 25 of 48 (52.1%) and 14 of 46 (30.4%) patients (RD, 20.8%; 95% CI: 1.6% to 40.0%), respectively. CONCLUSIONS: Fosfomycin is noninferior to ciprofloxacin as oral step-down treatment for fUTI caused by E. coli in women. Fosfomycin use is associated with more gastrointestinal events. CLINICAL TRIAL REGISTRATION: Trial NL6275 (NTR6449)